ABLYNX WINS AWARD FOR 'MOST SUCCESSFUL EARLY PHASE TRIAL'
(Thomson Reuters ONE) - GHENT, Belgium, 23 October 2009 - Ablynx [Euronext Brussels: ABLX] ispleased to announce it has been awarded 'Most Successful Early PhaseTrial' at the 2009 Good Clinical Practice Journal's (GCPj) ClinicalResearch Excellence Awards in London. The GCPj's Awards recogniseexcellence in clinical research and development.Commenting on the award, Chief Medical Officer Josi Holz said: "It isa great honour to receive this prestigious award. We are pleased thatour lead programme, a novel anti-thrombotic, ALX-0081 entered a PhaseII study in patients undergoing percutaneous coronary intervention(PCI) last month. The award recognises our innovative Phase Iclinical trial design and the acceleration of this programme throughthe use of biomarkers and PK/PD modelling to establish biologicaleffective dosing in patients. We have achieved the rapid progresswith ALX-0081 thanks to a dedicated Ablynx team and our collaboratorsat the OLVZ in Aalst and PRA International." -ends-About ALX-0681 and ALX-0081ALX-0681 and ALX-0081 are novel "first-in-class" therapeuticNanobodies® targeting von Willebrand factor ("vWF"), a protein foundin the blood that acts at a very early stage in the coagulationcascade, namely platelet adhesion, in contrast to currently availableanti-platelet drugs which act only in the late stage of plateletaggregation. ALX-0081 is administered intravenously while ALX-0681 isadministered subcutaneously. ALX-0081 is a bivalent Nanobody® with amolecular weight of 28,000 daltons, designed to selectively preventunwanted thrombus formation in vessels under high shear conditionswithout interfering with desirable haemostasis and, as such, tominimize bleeding complications.About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.comFounded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceuticalcompany focused on the discovery and development of Nanobodies®, anovel class of therapeutic proteins based on single-domain antibodyfragments, for a range of serious and life-threatening humandiseases. The Company currently has over 220 employees. Ablynxcompleted a successful IPO on Euronext Brussels [ABLX] on 7 November2007.For more information, please contact:College Hill Life Sciences - for UK/International media enquiries:Sue Charles, Justine Lamond, Dr John McIntyret: +44 (0)20 7866 7857e: ablynx(at)collegehill.comAblynx:Dr. Edwin MosesChairman and CEOt: +32 (0)9 262 00 07m: +44 (0)7771 954 193 / +32 (0)473 39 50 68e: edwin.moses(at)ablynx.comEva-Lotta AllanChief Business Officert: +32 (0)9 262 00 75m: +32 (0)475 78 36 21 / +44 (0)7990 570 900e: eva-lotta.allan(at)ablynx.comhttp://hugin.info/137912/R/1349787/325416.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 23.10.2009 - 18:00 Uhr
Sprache: Deutsch
News-ID 7368
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 450 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX WINS AWARD FOR 'MOST SUCCESSFUL EARLY PHASE TRIAL'"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
